Evidence map›Paper›PMID 40322383›Full record

ArticleCureus2025

Recurrent Chronic Idiopathic Urticaria Post-hysterectomy and Loss of Xolair Effectiveness: A Case Report.

Miriam Al-Saedy, Salsabeal Al-Saedy, David Robinson

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Miriam Al-SaedyInternal Medicine, Virginia Mason Medical Center, Seattle, USA.
Salsabeal Al-SaedyMedicine, Elson S. Floyd College of Medicine, Spokane, USA.
David RobinsonAllergy and Immunology, Virginia Mason Medical Center, Seattle, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the case of a 44-year-old woman with a history of chronic idiopathic urticaria (CIU) who initially achieved remission with omalizumab (Xolair) but experienced a relapse following a hysterectomy. Despite reinitiating treatment, her symptoms persisted, requiring escalating doses of antihistamines and systemic corticosteroids. This case highlights the potential role of hormonal shifts and surgical stress in triggering urticaria recurrence and contributing to biologic treatment failure, though causality remains unproven due to the lack of objective hormonal or immunologic data. It underscores the importance of closely monitoring treatment response over time and exploring alternative therapeutic strategies when standard approaches prove inadequate. Further research is needed to elucidate the mechanisms underlying post-surgical urticaria exacerbations and optimize long-term management for affected patients.

Indexed as

biologicbiologic treatmentchronic idiopathic urticariachronic spontaneuous urticariahivespost-op recurrence

Identifiers

PMID40322383
PMCPMC12048200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.